BR112012032540A2 - formulação de solução de lactona macrocíclica, e, uso da formulação veterinária - Google Patents

formulação de solução de lactona macrocíclica, e, uso da formulação veterinária

Info

Publication number
BR112012032540A2
BR112012032540A2 BR112012032540A BR112012032540A BR112012032540A2 BR 112012032540 A2 BR112012032540 A2 BR 112012032540A2 BR 112012032540 A BR112012032540 A BR 112012032540A BR 112012032540 A BR112012032540 A BR 112012032540A BR 112012032540 A2 BR112012032540 A2 BR 112012032540A2
Authority
BR
Brazil
Prior art keywords
formulation
macrocyclic lactone
veterinary
lactone solution
solution formulation
Prior art date
Application number
BR112012032540A
Other languages
English (en)
Inventor
Hyun Sun Cho
Perteson Fabiano Lopes
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44628008&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012032540(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112012032540A2 publication Critical patent/BR112012032540A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

formulação de solução de lactona macrocíclica, e, uso da formulação veterinária.a presente invenção refere-se a formulações para controlar parasitas, compreendendo a combinação de um composto de lactona macrocíclica e levamisol em que o levamisol está em forma particulada em suspensão em um solvente não aquoso.
BR112012032540A 2010-06-24 2011-06-23 formulação de solução de lactona macrocíclica, e, uso da formulação veterinária BR112012032540A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10167222 2010-06-24
US42084910P 2010-12-08 2010-12-08
PCT/EP2011/060535 WO2011161209A1 (en) 2010-06-24 2011-06-23 Injectable formulation of a macrocyclic lactone and levamisole

Publications (1)

Publication Number Publication Date
BR112012032540A2 true BR112012032540A2 (pt) 2016-11-22

Family

ID=44628008

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012032540A BR112012032540A2 (pt) 2010-06-24 2011-06-23 formulação de solução de lactona macrocíclica, e, uso da formulação veterinária

Country Status (9)

Country Link
US (1) US20130090296A1 (pt)
EP (1) EP2585062A1 (pt)
AR (1) AR081970A1 (pt)
AU (1) AU2011268899C1 (pt)
BR (1) BR112012032540A2 (pt)
MX (1) MX336924B (pt)
NZ (1) NZ603775A (pt)
WO (1) WO2011161209A1 (pt)
ZA (1) ZA201209445B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010101089B4 (en) * 2010-10-06 2013-03-07 Jurox Pty Limited Parasiticidal Composition
AU2010101389C4 (en) * 2010-12-08 2017-03-02 Jurox Pty Ltd Anthelmintic formulation
AU2012227241C1 (en) * 2011-09-23 2017-01-19 Virbac (Australia) Pty Limited Veterinary Topical Formulation
NZ701697A (en) 2014-03-24 2016-05-27 Donaghys Ltd Stable veterinary anthelmintic formulations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
US3984564A (en) 1972-06-08 1976-10-05 Sankyo Company Limited Antibiotic substances B-41, their production and their use as insecticides and acaricides
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
ES8800986A1 (es) 1985-07-27 1987-12-01 Pfizer Un procedimiento para la produccion de un nuevo derivado de avermectina
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
IL98599A (en) 1990-06-28 1995-06-29 Merck & Co Inc Stable salts of "4-deoxy-" 4-epi-methylamino abramectin and insecticides containing them
NZ335166A (en) 1999-04-14 2001-11-30 Ashmont Holdings Ltd Anthelmintic composition containing triclabendazole in at least one solvent
US5399717A (en) 1993-09-29 1995-03-21 Merck & Co., Inc. Glycosidation route to 4"-epi-methylamino-4"-deoxyavermectin B1
AU772988B2 (en) 1999-06-04 2004-05-13 Elanco Tiergesundheit Ag Stable biocidal compositions
CN1375291A (zh) * 2001-03-16 2002-10-23 王玉万 一种含左旋咪唑或其盐类的兽用复方注射剂
NZ520295A (en) * 2002-07-19 2005-04-29 Ashmont Holdings Ltd Anthelmintic formulations comprising levamisole and either an avermectin or milbemycin
NZ552040A (en) * 2006-12-13 2009-04-30 Bomac Research Ltd Veterinary formulation comprising an anthelmintic compound and glyceryl acetate
CA2734459A1 (en) * 2008-08-18 2010-02-25 Intervet International B.V. Anthelmintic compositions

Also Published As

Publication number Publication date
AU2011268899C1 (en) 2020-03-05
ZA201209445B (en) 2013-08-28
AU2011268899A1 (en) 2012-12-13
US20130090296A1 (en) 2013-04-11
MX2012015193A (es) 2013-01-24
EP2585062A1 (en) 2013-05-01
NZ603775A (en) 2015-01-30
MX336924B (es) 2016-02-05
AU2011268899B2 (en) 2016-07-07
AR081970A1 (es) 2012-10-31
WO2011161209A1 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
UY34350A (es) Derivados de pirazolquinolinona, su preparación y su uso terapéutico.
BR112014029115A2 (pt) composto, composição farmacêutica, e, uso de um composto ou composição
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
UY33396A (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
CL2013002123A1 (es) Composicion herbicida que comprende topramezona y pinoxaden; uso de dicha composicion para controlar vegetación indeseable; formulación indeseable.
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013030302A2 (pt) composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo
CL2014002348A1 (es) Compuestos derivados de fenicol; composicion farmaceutica que los comprende; y su uso para controlar o tratar infecciones bacterianas en ganado.
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
CL2015003357A1 (es) Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos
ES2408343R1 (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
BR112014029642A2 (pt) composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
BR112014023193A2 (pt) composto da fórmula geral (i): a[l-ch-ca]p e formulação de vacina
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
BR112016001876A2 (pt) composto de benzoxaborol tricíclico, método de preparação e uso do mesmo
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112012032540A2 (pt) formulação de solução de lactona macrocíclica, e, uso da formulação veterinária
CO6980142A1 (es) Composición de catalizador que se propone para el uso con composiciones puzolánicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2516 DE 26/03/2019 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]